Organoids can be transformative tools in biomedical research. These miniature organ-like structures are derived from stem cells, possessing a three-dimensional (3D) architecture and multiple cell types, unlike traditional two-dimensional (2D) cell cultures.
Their ability to closely mimic the structural and functional properties of native organs makes organoids highly versatile, scalable platforms. They’re perfect for studying human biology in a controlled laboratory setting.
Demand for these models is surging with evolving regulatory landscapes. For example, the U.S. Food and Drug Administration (FDA) announced plans to phase out certain animal testing requirements in April 2025, specifically promoting organoids as superior, human-based alternatives suitable for drug development.
Over 180 organoid-related clinical studies were registered by mid-2025. The industry is rapidly transitioning towards these high-fidelity systems for precision medicine and drug-sensitivity testing.
Figure 1. Diverse applications of organoid technology. Image Credit: (Image from Corrò et al. used under CC BY 4.0. https://doi.org/10.1152/ajpcell.00120.2020)
Technical challenges in organoid culture
While they have potential, for organoids, the path from bench to bedside is hindered by continuing technical challenges. These include:
- Limited scalability and insufficient tissue maturation
- Restricted access to high-performance, clinically compatible reagents
- The risk of compromised experimental reproducibility due to batch-to-batch variability
- Endotoxin contamination with the potential to activate innate immune signaling, induce stress responses, and alter cellular metabolism, ultimately confounding drug response data
Sino Biological’s 3D organoid research solutions
Sino Biological is working to address these challenges through its comprehensive portfolio of high-quality cytokines, small molecules, growth factors, and marker antibodies, all designed for organoid culture and characterization.
The company’s research solutions have been optimized to accommodate almost 30 popular tumor and physiological organoid models, with great support for disease modeling, oncology, and drug screening applications.
For instance, Jianqing Liang, PhD, and his colleagues at Fudan University used Sino Biological’s recombinant human EGF protein (Cat#: 10605-HNAE) to establish an optimized culture system for human fetal thyroid organoids (hFTOs).2
Figure 2A shows a schematic diagram of fetal thyrocyte digestion and seeding, along with the culture medium for hFTOs. Figure 2B features the time-point bright-field images of hFTOs.
Figure 2. Generation of reproducible human fetal thyroid organoids (hFTOs). Image Credit: (Image from Liang et al. used under CC BY 4.0. https://doi.org/10.1002/advs.202105568)
Sino Biological has a consolidated hub of technical guidelines, brochures, and expert-led webinars designed to further support the scientific community and streamline organoid research workflows.
The ProPure™ advantage: Ensuring culture integrity
Recombinant cytokines and growth factors play key roles in organoid culture systems, directing stem cell differentiation, sustaining long-term growth, and maintaining tissue identity. Trace levels of endotoxin contamination can significantly disrupt 3D cultures, however, altering cellular metabolism, activating innate immune signaling pathways, and inducing stress responses or cell death.
These unintended effects can obscure true disease phenotypes, compromise experimental reproducibility, and confound drug response data, especially when working with sensitive, patient-derived organoid models.
ProPure™ endotoxin-free proteins from Sino Biological allow researchers to establish robust, translationally relevant organoid platforms.
These highly purified preparations are designed to minimize inflammatory artifacts, ensure consistent lineage specification, and reduce batch-to-batch variability across large-scale cultures. The reagents help confirm that observed biological responses in high-throughput drug screening and preclinical studies arise from therapeutic candidates rather than culture-induced artifacts.
This is key to ensuring confident data interpretation and robust, regulatory-facing research workflows.
Conclusion
Organoid technology continues to revolutionize disease modeling and drug discovery by providing physiologically relevant, human-based platforms. For these platforms to fully realize their translational potential, they must overcome challenges such as limited scalability, variability, and endotoxin interference.
Sino Biological empowers researchers to build robust, reproducible organoid systems by offering high-quality, endotoxin-free reagents and comprehensive technical support to accelerate therapeutic development and scientific innovation.
References and further reading
- Corrò, C., Novellasdemunt, L. and Li, V.S.W. (2020). A brief history of organoids. American Journal of Physiology-Cell Physiology, 319(1), pp.C151–C165. DOI: 10.1152/ajpcell.00120.2020. https://journals.physiology.org/doi/10.1152/ajpcell.00120.2020.
- Liang, J., et al. (2022). Modeling Human Thyroid Development by Fetal Tissue‐Derived Organoid Culture. Advanced Science, 9(9), p.2105568. DOI: 10.1002/advs.202105568. https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202105568.
Acknowledgments
Produced from materials originally authored by Sino Biological.
About Sino Biological Inc.
Sino Biological is an international supplier and service provider of reagents. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies, and cDNA clones. Sino Biological is the one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.
Sino Biological's core business
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to serving as a one-stop technical services shop for life science researchers worldwide. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.